Non-fucosylated therapeutic antibodies: The next generation of therapeutic antibodies

Cytotechnology

Volumn 55, Issue 2-3, 2007, Pages 109-114

  Mori, Katsuhiro ^a   Iida, Shigeru ^a   Yamane Ohnuki, Naoko ^a   Kanda, Yutaka ^a   Kuni Kamochi, Reiko ^a   Nakano, Ryosuke ^a   Imai Nishiya, Harue ^a   Okazaki, Akira ^a   Shinkawa, Toyohide ^a   Natsume, Akihito ^a   Niwa, Rinpei ^a   Shitara, Kenya ^a   Satoh, Mitsuo ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

1,6 fucosyltransferase (FUT8) knockout; ADCC; Chinese hamster ovary (CHO); Core fucosylation; Fc RIIIa binding; Human plasma IgG; N linked Fc oligosaccharide; Therapeutic antibody

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INFLIXIMAB; NATALIZUMAB; OMALIZUMAB; PALIVIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; ZENEPAX;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; HUMAN; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS; VIRUS INFECTION;

CRICETULUS GRISEUS;

EID: 36749037760     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-007-9103-2     Document Type: Review

References (45)

1. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459
2. Baker M (2005) Upping the ante on antibodies. Nat Biotechnol 23:1065-1072
3. Baselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12(Suppl 1):S35-S41
4. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001
5. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
6. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669
7. de Bono JS, Rowinsky EK (2002) The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8(4 Suppl):S19-S26
8. Forero A, Lobuglio AF (2003) History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 30:1-5
9. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS (2002) Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117:828-834
10. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655
11. Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309-318
12. Grillo-Lopez AJ (2003) Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 3:767-769
13. Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A (1987) Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 164:374-381
14. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M (2006) Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγIIIa. Clin Cancer Res 12:2879-2887
15. Jahrsdorfer B, Weiner GJ (2003) Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol 30:476-482
16. Jefferis R (2001) Glycosylation of human IgG antibodies: relevance to therapeutic applications. BioPharm 14:19-26
17. Jefferis R (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21:11-16
18. Kamoda S, Nomura C, Kinoshita M, Nishiura S, Ishikawa R, Kakehi K, Kawasaki N, Hayakawa T (2004) Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis. J Chromatogr A 1050:211-216
19. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M (2006) Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 94:680-688
20. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010
21. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263
22. Mizuochi T, Taniguchi T, Shimizu A, Kobata A (1982) Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020
23. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K, Shitara K, Satoh M (2004) Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88:901-908
24. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K (2005) Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 306:93-103
25. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K (2004a) Defucosylated anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res 64:2127-2133
26. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K (2004b) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgRIIIa functional polymorphism. Clin Cancer Res 10:6248-6255
27. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K (2005a) Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336
28. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K (2005b) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306:151-160
29. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol 336:1239-1249
30. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS (2006) High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immnunoglobulin G. Mol Immunol 43:1183-1193
31. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev Biochem 57:785-838
32. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073-1078
33. Satoh M, Iida S, Shitara K (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6:1161-1173
34. Schenerman MA, Hope JN, Kletke C, Singh JK, Kimura R, Tsao EI, Folena-Wasserman G (1999) Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. Biologicals 27:203-215
35. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276:6591-6604
36. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta L (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740
37. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473
38. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70
39. Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T (2001) Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 248:103-111
40. Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao CX, Teshima T, Fujii S, Shiba T, Taniguchi N (1996) Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-d-glucosaminide alpha1,6fucosyltransferase. J Biol Chem 271:27810-27817
41. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63:5595-5600
42. Vogel CL, Franco SX (2003) Clinical experience with trastuzumab (herceptin). Breast J 9:452-462
43. Vugmeyster Y, Howell K (2004) Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol 4:1117-1124
44. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947
45. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87:614-622